Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Midazolam,Ketamine Hydrochloride,Ondansetron
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Approved FDF
Sponsor : iOR Partners
Deal Size : Undisclosed
Deal Type : Agreement
Harrow and iOR Partners Expand National Product Supply Agreement
Details : The MKO melt (midazolam) is being marketed as an anesthetic medication for cataract surgery that has the advantage that it eliminates the need for an IV in 85% of patients although that number was established anecdotally.
Product Name : MKO Melt
Product Type : Controlled Substance
Upfront Cash : Undisclosed
November 30, 2022
Lead Product(s) : Midazolam,Ketamine Hydrochloride,Ondansetron
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Approved FDF
Sponsor : iOR Partners
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Midazolam,Ketamine Hydrochloride,Ondansetron
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study on Patented Non-Opioid MKO Melt® Reported in Leading Peer-Reviewed Anesthesia Journal
Details : Each sublingually administered MKO Melt troche contains 3 mg of midazolam, 25 mg of ketamine, and 2 mg of ondansetron, and is available for institutional purchase through Harrow’s wholly-owned subsidiary, ImprimisRx®.
Product Name : MKO Melt
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 03, 2020
Lead Product(s) : Midazolam,Ketamine Hydrochloride,Ondansetron
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable